spacer
Topic quick links:
Cover page
spacer
All articles in this issue:
 Drugs in prisons
 Fifth ESPAD survey report published
 First report of National Suicide Support and Information System
 Measuring the performance of drugs task forces and evaluating projects
 National Registry of Deliberate Self Harm annual report 2011
 National survey of youth mental health
 Non-fatal overdoses and drug-related emergencies 2010
 Poisoning and clinical toxicology: a template for Ireland
 Trends in alcohol and drug admissions to psychiatric facilities
 Public support for measures to address alcohol use
 Report of the Strategic Response Group – ‘A better city for all’
 Parental responsibilities and drug treatment outcomes
 The views of children and young people in state care
 Unmet needs and benzodiazepine misuse among people in treatment
 Deaths among children and young people in state care, after care or known to the HSE
 Drug use among the general population, by regional drugs task force area
 The National Documentation Centre on Drug Use: survey results
 Drugnet digest
 In brief
 Drugs and crime data 2012
 Drugs in focus – policy briefing
 From Drugnet Europe
 Recent publications
 Upcoming events
 EU drugs policy – what next?
 EMCDDA trend report for the evaluation of the 2005–2012 EU drugs strategy
 Alternative ways forward for EU drugs policy
Drug use among the general population, by regional drugs task force area
by Jean Long and Justine Horgan

Cover - Drug use among the general populationOn 19 June a new bulletin was published outlining drug prevalence data by regional drugs task force (RDTF) area based on findings from the 2010/2011 National Advisory Committee on Drug’s general population survey on drug use.1 This is the third of these surveys, previously done in 2002/3 and 2006/7.

Drug prevalence surveys of the general population are important in that they can shed light on the patterns of drug use, both demographically and geographically and, when repeated, can track changes over time. The Irish survey followed best practice guidelines recommended by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The commentary in this article concentrates on the prevalence of drug use in the year prior to the survey (described as ‘recent’ use) as this is the most useful measure for policy makers and service planners.

  • Recent (or last-year) illicit drug use among the 15–64-year-old population stabilised or decreased marginally in most RDTF areas between 2006/7 and 2010/11, with no area showing a significant increase (Table 1). As expected, recent use is higher among men than women and higher among those aged 15–34 years than among their older counterparts.
  • Cannabis was the most commonly reported illegal drug used in each of the RDTF areas, with rates of recent use ranging between 2.8% in the North West and 9.4% in North Dublin (Table 2 and Figure 1). Rates have stabilised or fallen in six RDTF areas (though not statistically significantly) and increased significantly in one area, the Western RDTF.
  • Recent ecstasy use decreased somewhat in all RDTF areas (significantly so in the East Coast area only), with proportions ranging between 0% in the North West and 1.3% in North Dublin. (Table 3). Anecdotal reports of seizures and adverse events through early warning reports indicate that ecstasy use increased in late 2011 and 2012.
  • Cocaine was the second most common illicit drug used in the year prior to the survey (Table 4).  Its use was highest in the North Dublin, South West and East Coast RDTF areas. Recent cocaine use stabilised or decreased somewhat in nine areas and increased significantly in only one, the South West (SW Dublin, W Wicklow and Kildare).
  • Recent use of new psychoactive substances was reported in all RDTF areas. The rate of use was highest in the East Coast (7.7%) and lowest in the North West (1.5%). It has been suggested that new psychoactive substances may take the place of other stimulants, which may account for the marginal decrease in cocaine and ecstasy use since 2006/7.2 Anecdotally, the use of new psychoactive substances appears to have decreased, which is evidenced by a reduction in the number of adverse events reported since the introduction of relevant legislation.
  • Recent use of sedatives and tranquillisers (such as benzodiazepines and zopiclone, both prescribed and non-prescribed) has increased significantly in three RDTF areas (North Dublin, South West and North Eastern) and decreased significantly in the North West. Sedatives and tranquilisers are among the four most common drugs used in all RDTF areas (Figure 1).
  • The definition of the category ‘other opiates’ was broadened in successive surveys, to be consistent with the definition used in Northern Ireland, and to include substances that contain codeine (an opiate). Consequently, data from the 2010/11 survey on recent use of ‘other opiates’ is not comparable with data for that category in previous surveys  In 2010/11 the rate of recent use of other opiates is high in all RDTF areas, ranging from 19.1% in the North West to  37.5% in the Western area (Figure 1).

Table 1   Proportion of respondents aged 15–64 who reported lifetime and last-year use of illegal drugs, by regional drugs task force area of residence

 drug_use_general_population_table_1.jpg


Table 2   Proportion of respondents aged 15–64 who reported lifetime and last-year use of cannabis, by regional drugs task force area of residence

 drug_use_general_population_table_2.jpg


Table 3   Proportion of respondents aged 15–64 who reported lifetime and last-year use of ecstasy, by regional drugs task force area of residence

drug_use_general_population_table_3.jpg


Table 4   Proportion of respondents aged 15–64 who reported lifetime and last-year use of cocaine, by regional drugs task force area of residence

drug_use_general_population_table-4.jpg


drug_use-general_population_figure_1_map.jpg
Figure 1   Last-year prevalence among the general population of the most commonly used legal and illegal drugs (excluding alcohol), by regional drugs task force area, 2010/11
Data source: National Advisory Committee on Drugs and Public Health Information Branch (2012)



Newsletter Marketing Powered by Newsweaver